William Blair analyst Dylan Becker maintained a Buy rating on Enfusion (ENFN – Research Report) today. The company’s shares closed today at $9.68.
Becker covers the Technology sector, focusing on stocks such as Ansys, Autodesk, and Guidewire. According to TipRanks, Becker has an average return of 9.4% and a 69.12% success rate on recommended stocks.
Enfusion has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Enfusion’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $44.36 million and a net profit of $1.83 million. In comparison, last year the company earned a revenue of $39.15 million and had a net profit of $1.54 million
Based on the recent corporate insider activity of 92 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ENFN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enfusion (ENFN) Company Description:
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.
Read More on ENFN:
